

# St. Jude LIFE

***Establishment of a Lifetime Cohort of Adults  
Surviving Childhood Cancer***



## **Data Tables**

**St. Jude Children's  
Research Hospital**

June 30, 2015

Data Freeze

October 15, 2015




Data Tables and Figures for SJLIFE  
Participants and Non-Participants  
through June 30, 2015



# Table of Contents

Consort Diagram.....	1
Table 1. SJLIFE Campus Visit Participation Rates by Block.....	2
Table 2. Demographic and Diagnostic Characteristics of SJLIFE Participants.....	3
Table 3. Demographic and Diagnostic Characteristics of SJLIFE Campus Visit Participants and Non-Participants.....	5
Table 4a. SJLIFE Campus Visit Participants by Primary Diagnosis and Years from Diagnosis.....	7
Table 4b. SJLIFE Campus Visit Participants by Primary Diagnosis and Age at Last Visit.....	8
Table 5. Route and Chemotherapy Specific Percentile Dose Distributions Among SJLIFE Campus Visit Participants.....	9
Table 6. Radiation Exposure Among SJLIFE Campus Visit Participants by Primary Diagnosis and Treatment Field.....	13
SJLIFE Concept Registry (Link).....	14

# SJLIFE Study Status as of June 30, 2015



*Table 1. SJLIFE Campus Visit Participation Rates by Block\**

Block Number	Number of Participants	Participation Rate (%)	Block Number	Number of Participants	Participation Rate (%)	Block Number	Number of Participants	Participation Rate (%)
1	39	76.5	36	1242	71.6	71	2280	67.6
2	76	76.8	37	1270	71.3	72	2306	67.5
3	109	73.2	38	1301	71.1	73	2335	67.4
4	138	70.1	39	1336	71.1	74	2362	67.3
5	176	72.1	40	1374	71.3	75	2388	67.2
6	207	70.6	41	1416	71.7	76	2417	67.1
7	245	71.6	42	1449	71.6	77	2443	67.0
8	282	72.9	43	1478	71.4	78	2470	66.9
9	326	74.8	44	1506	71.1	79	2491	66.6
10	358	73.8	45	1543	71.3	80	2518	66.5
11	394	73.8	46	1573	71.1	81	2552	66.6
12	430	74.0	47	1607	71.1	82	2586	66.7
13	463	73.4	48	1637	70.9	83	2611	66.7
14	492	72.9	49	1675	71.0	84	2622	66.6
15	526	72.9	50	1707	71.0	85	2648	66.6
16	564	73.2	51	1738	70.8	86	2672	66.5
17	602	73.6	52	1769	70.6	87	2704	66.6
18	642	74.0	53	1795	70.4	88	2737	66.6
19	676	74.0	54	1824	70.3	89	2771	66.7
20	712	74.0	55	1848	70.1	90	2800	66.6
21	742	73.4	56	1874	69.9	91	2825	66.4
22	773	73.0	57	1897	69.5	92	2850	66.3
23	804	72.6	58	1923	69.3	93	2873	66.1
24	836	72.3	59	1951	69.3	94	2901	66.0
25	874	72.5	60	1976	69.0	95	2929	65.9
26	909	72.4	61	2009	69.0	96	2955	65.8
27	941	72.1	62	2037	68.9	97	2980	65.6
28	975	72.2	63	2060	68.6	98	3004	65.5
29	1010	72.2	64	2088	68.5	99	3034	65.4
30	1043	72.1	65	2114	68.3	100	3053	65.1
31	1079	72.2	66	2147	68.3	101	3058	64.6
32	1110	71.8	67	2177	68.3	102	3061	63.9
33	1147	72.0	68	2205	68.2	103	3062	63.3
34	1181	72.0	69	2228	67.9	104	3063	62.7
35	1212	71.8	70	2255	67.7			

\*Study status as of June 30, 2015

*Table 2. Demographic and Diagnostic Characteristics of SJLIFE Participants (N=3308)\**

Characteristic		Total N (%)	Campus Visit N (%)	Survey Only N (%)
All Participants		3308	3063	245
<b>Sex</b>	Female	1599 (48.3)	1467 (47.9)	132 (53.9)
	Male	1709 (51.7)	1596 (52.1)	113 (46.1)
<b>Race</b>	White	2790 (84.3)	2571 (83.9)	219 (89.4)
	Black	467 (14.1)	442 (14.4)	25 (10.2)
	Other	51 (1.5)	50 (1.6)	1 (0.4)
<b>Hispanic Ethnicity</b>	Yes	63 (1.9)	63 (2.1)	0 (0.0)
	No	3245 (98.1)	3000 (97.9)	245 (100.0)
<b>Primary Diagnosis</b>	Acute lymphoblastic leukemia	1077 (32.6)	1008 (32.9)	69 (28.2)
	Acute myeloid leukemia	127 (3.8)	114 (3.7)	13 (5.3)
	Other leukemia	24 (0.7)	21 (0.7)	3 (1.2)
	Other hematologic malignancy	20 (0.6)	19 (0.6)	1 (0.4)
	CNS tumor	343 (10.4)	312 (10.2)	31 (12.7)
	Ewing sarcoma family of tumors	97 (2.9)	92 (3.0)	5 (2.0)
	Osteosarcoma	127 (3.8)	116 (3.8)	11 (4.5)
	Germ cell tumor	78 (2.4)	69 (2.3)	9 (3.7)
	Hepatoblastoma	22 (0.7)	20 (0.7)	2 (0.8)
	Hodgkin lymphoma	401 (12.1)	368 (12.0)	33 (13.5)
	Non-Hodgkin lymphoma	242 (7.3)	223 (7.3)	19 (7.8)
	Melanoma	19 (0.6)	16 (0.5)	3 (1.2)
	Neuroblastoma	144 (4.4)	138 (4.5)	6 (2.4)
	Retinoblastoma	97 (2.9)	90 (2.9)	7 (2.9)
	Rhabdomyosarcoma (RMS)	114 (3.4)	107 (3.5)	7 (2.9)
	Non-RMS	89 (2.7)	83 (2.7)	6 (2.4)
	Wilms tumor	218 (6.6)	202 (6.6)	16 (6.5)
	Carcinomas	51 (1.5)	47 (1.5)	4 (1.6)
	Other malignancy	14 (0.4)	14 (0.5)	0 (0.0)
	Other neoplasm	4 (0.1)	4 (0.1)	0 (0.0)

\*Study status as of June 30, 2015



**Table 2 Cont'd. Demographic and Diagnostic Characteristics of SJLIFE Participants (N=3308)\***

Characteristic		Total N (%)	Campus Visit N (%)	Survey Only N (%)
<b>Age at Diagnosis (Years)</b>	Mean +/- sd	7.9 +/- 5.6	7.8 +/- 5.6	8.7 +/- 5.8
	Median	7.0	7.0	8.0
	Range	0.0-24.0	0.0-24.0	0.0-21.0
	<1		185 (6.0)	13 (5.3)
	1 - 4		963 (31.4)	64 (26.1)
	5 - 9		719 (23.5)	60 (24.5)
	10 - 14		700 (22.9)	56 (22.9)
	15 - 19		474 (15.5)	46 (18.8)
	20 - 24		22 (0.7)	6 (2.4)
<b>Diagnosis to Visit/Survey</b>	Mean +/- sd		23.6 +/- 8.2	26.4 +/- 8.1
	Median		22.5	25.8
	Range		10.4-49.8	11.6-46.8
	10 - 19		1181 (38.6)	58 (23.7)
	20 - 29		1178 (38.5)	104 (42.4)
	30 - 39		599 (19.6)	71 (29.0)
	40 - 49		105 (3.4)	12 (4.9)
<b>Age at Visit/Survey (Years)</b>	Mean +/- sd		31.4 +/- 8.4	35.1 +/- 9.3
	Median		30.0	34.0
	Range		18.0-64.0	18.0-63.0
	18 - 24		760 (24.8)	34 (13.9)
	25 - 29		647 (21.1)	45 (18.4)
	30 - 34		646 (21.1)	47 (19.2)
	35 - 39		465 (15.2)	37 (15.1)
	40 - 44		301 (9.8)	40 (16.3)
	45 - 49		159 (5.2)	26 (10.6)
	50 - 64		85 (2.8)	16 (6.5)

\*Study status as of June 30, 2015

**Table 3. Demographic and Diagnostic Characteristics of SJLIFE  
Campus Visit Participants (N=3063) and Non-Participants (N=1381)\***

Characteristic	Total	Campus Visit N (%)	Non-Participants N (%)	P-value
All	4444	3063	1381	
<b>Sex</b>				
Female	2004	1467 (47.9)	537 (38.9)	<.001
Male	2440	1596 (52.1)	844 (61.1)	
<b>Race</b>				
White	3700	2571 (83.9)	1129 (81.8)	0.196
Black	668	442 (14.4)	226 (16.4)	
Other	76	50 (1.6)	26 (1.9)	
<b>Hispanic</b>				
Yes	95	63 (2.1)	32 (2.3)	0.579
No	4349	3000 (97.9)	1349 (97.7)	
<b>Primary Diagnosis</b>				
Acute lymphoblastic leukemia	1416	1008 (32.9)	408 (29.5)	0.017
Acute myeloid leukemia	169	114 (3.7)	55 (4.0)	
Other leukemia	38	21 (0.7)	17 (1.2)	
Other hematologic malignancy	32	19 (0.6)	13 (0.9)	
CNS tumor	448	312 (10.2)	136 (9.8)	
Ewing sarcoma family of tumors	125	92 (3.0)	33 (2.4)	
Osteosarcoma	158	116 (3.8)	42 (3.0)	
Germ cell tumor	115	69 (2.3)	46 (3.3)	
Hepatoblastoma	38	20 (0.7)	18 (1.3)	
Hodgkin lymphoma	508	368 (12.0)	140 (10.1)	
Non-Hodgkin lymphoma	351	223 (7.3)	128 (9.3)	
Melanoma	29	16 (0.5)	13 (0.9)	
Neuroblastoma	203	138 (4.5)	65 (4.7)	
Retinoblastoma	126	90 (2.9)	36 (2.6)	
Rhabdomyosarcoma (RMS)	160	107 (3.5)	53 (3.8)	
Non-RMS	132	83 (2.7)	49 (3.5)	
Wilms tumor	299	202 (6.6)	97 (7.0)	
Carcinomas	68	47 (1.5)	21 (1.5)	
Other malignancy	23	14 (0.5)	9 (0.7)	
Other neoplasm	6	4 (0.1)	2 (0.1)	

\*Study status as of June 30, 2015

**Table 3 Cont'd. Demographic and Diagnostic Characteristics of SJLIFE  
Campus Visit Participants (N=3063) and Non-Participants (N=1381)\*`**

Characteristic		Total	Campus Visit N (%)	Non- Participants N (%)	P-value
<b>Age at Diagnosis (Years)</b>	<1	286	185 (6.0)	101 (7.3)	0.629
	1 - 4	1396	963 (31.4)	433 (31.4)	
	5 - 9	1051	719 (23.5)	332 (24.0)	
	10 - 14	996	700 (22.9)	296 (21.4)	
	15 - 19	683	474 (15.5)	209 (15.1)	
	20 - 28	32	22 (0.7)	10 (0.7)	
<b>Years from Diagnosis as of June 30, 2015</b>	11 - 19	1013	673 (22.0)	340 (24.6)	0.232
	20 - 29	1696	1172 (38.3)	524 (37.9)	
	30 - 39	1282	899 (29.4)	383 (27.7)	
	40 - 53	453	319 (10.4)	134 (9.7)	
<b>Age as of June 30, 2015</b>	18 - 24	545	327 (10.7)	218 (15.8)	<.001
	25 - 29	775	535 (17.5)	240 (17.4)	
	30 - 34	925	662 (21.6)	263 (19.0)	
	35 - 39	807	559 (18.3)	248 (18.0)	
	40 - 44	635	436 (14.2)	199 (14.4)	
	45 - 49	409	300 (9.8)	109 (7.9)	
	50 - 70	348	244 (8.0)	104 (7.5)	

\*Study status as of June 30, 2015

**Table 4a. SJLIFE Campus Visit Participants by Primary Diagnosis and Years from Diagnosis (N=3063)\***

Primary Diagnosis	Years from Diagnosis as of June 30, 2015				Total
	11 to 19	20 to 29	30 to 39	40 to 53	
Acute lymphoblastic leukemia	162	353	357	136	1008
Acute myeloid leukemia	41	44	26	3	114
Other leukemia	6	11	3	1	21
Other hematologic malignancy	2	5	10	2	19
CNS tumor	149	153	6	4	312
Ewing sarcoma family of tumors	22	43	23	4	92
Osteosarcoma	30	35	42	9	116
Germ cell tumor	16	27	22	4	69
Hepatoblastoma	.	10	7	3	20
Hodgkin lymphoma	94	136	92	46	368
Non-Hodgkin lymphoma	49	78	82	14	223
Melanoma	6	5	4	1	16
Neuroblastoma	8	55	55	20	138
Retinoblastoma	4	25	38	23	90
RMS	23	43	31	10	107
Non-RMS	22	41	13	7	83
Wilms tumor	16	82	75	29	202
Carcinomas	16	19	9	3	47
Other malignancy	5	6	3	.	14
Other neoplasm	2	1	1	.	4
<b>Total</b>	<b>673</b>	<b>1172</b>	<b>899</b>	<b>319</b>	<b>3063</b>

\*Study status as of June 30, 2015

**Table 4b. SJLIFE Campus Visit Participants by Primary Diagnosis and Age at Last Visit (N=3063)\***

Primary Diagnosis	Age at Last Visit							Total
	18 - 24	25 - 29	30 - 34	35 - 39	40 - 44	45 - 49	50 - 66	
Acute lymphoblastic leukemia	224	172	218	150	127	77	40	1008
Acute myeloid leukemia	33	14	32	16	12	6	1	114
Other leukemia	4	2	7	3	3	1	1	21
Other hematologic malignancy	4	2	7	4	2	.	.	19
CNS tumor	115	111	60	21	2	.	3	312
Ewing sarcoma family of tumors	13	14	20	14	16	5	10	92
Osteosarcoma	9	17	22	15	14	25	14	116
Germ cell tumor	18	10	15	13	7	3	3	69
Hepatoblastoma	10	2	3	2	3	.	.	20
Hodgkin lymphoma	16	47	69	75	57	56	48	368
Non-Hodgkin lymphoma	29	33	46	43	36	21	15	223
Melanoma	4	3	6	.	.	1	2	16
Neuroblastoma	38	35	26	20	12	6	1	138
Retinoblastoma	24	12	12	23	13	6	.	90
RMS	22	22	25	15	12	8	3	107
Non-RMS	15	17	19	15	7	8	2	83
Wilms tumor	48	44	46	30	15	11	8	202
Carcinomas	8	8	8	12	7	2	2	47
Other malignancy	2	2	5	2	1	.	2	14
Other neoplasm	1	.	2	1	.	.	.	4
<b>Total</b>	<b>637</b>	<b>567</b>	<b>648</b>	<b>474</b>	<b>346</b>	<b>236</b>	<b>155</b>	<b>3063</b>

\*Study status as of June 30, 2015

**Table 5. Route and Chemotherapy Specific Percentile Dose Distributions among SJLIFE Campus Visit Participants (N=3063)\***

Cumulative Dose (when known): Percentiles									
Chemotherapy Agent	Route	Units/m <sup>2</sup>	N	10th	25th	50th	75th	90th	
5-Azacytidine	Intravenous	mg	28	594	600	600	828	1800	
6-Azauridine	Intravenous	mg	19	14943	90000	144231	163362	221391	
9-Aminocamptothecin	Intravenous	mg	1	66	66	66	66	66	
Aldesleukin (Interleukin-2)	Intravenous	million	5	49	60	60	130	216	
	Subcutaneous	million	2	67	67	78	90	90	
Alpha Interferon	Intramuscular	million	1	1884	1884	1884	1884	1884	
	Subcutaneous	million	9	82	265	623	989	20500	
Amifostine	Intravenous	mg	5	4725	4725	4782	4839	4839	
Amsacrine	Intravenous	mg	20	374	375	375	798	1337	
Anastrozole (Arimidex)	Oral	mg	3	.	.	.	.	.	
Arsenic Trioxide (Trisenox)	Intravenous	mg	2	291	291	305	318	318	
Bevacizumab (Avastin)	Intravenous	mg	3	4305	4305	6801	9298	9298	
Bleomycin	Intravenous	units	148	30	40	60	79	119	
Brentuximab vedotin	Intravenous	mg	1	380	380	380	380	380	
Busulfan	Intravenous	mg	8	327	367	518	597	638	
	Oral	mg	21	331	369	440	526	569	
Capecitabine (Xeloda)	Oral	mg	3	1875	1875	1875	1875	1875	
Carboplatin	Intravenous	mg	157	974	1642	2793	3926	5179	
Carmustine	Intravenous	mg	13	97	101	192	300	465	
Chlorambucil (Leukeran)	Intravenous	mg	2	59	59	65	71	71	
Cisplatin	Intravenous	mg	245	185	293	400	473	625	
	Cladribine	Intravenous	mg	49	44	45	45	88	90
		Cyclophosphamide	Intravenous	mg	1546	1855	3618	7202	10162
Oral	mg		273	3569	4285	6816	12064	18815	
Subcutaneous	mg		1	100	100	100	100	100	
Cyclosporine	Oral	mg	4	269674	269674	269674	269674	269674	
Cytarabine	Intramuscular	mg	1	6100	6100	6100	6100	6100	
	Intraommaya	mg	6	99	208	315	663	752	
	Intrathecal	mg	816	166	325	499	720	950	
	Intravenous	mg	970	1000	1960	5147	10002	11184	
	Subcutaneous	mg	61	750	1388	4412	8699	10237	

\*Study status as of June 30, 2015

Cumulative Dose (when known): Percentiles								
Chemotherapy Agent	Route	Units/m <sup>2</sup>	N	10th	25th	50th	75th	90th
Cytarabine: High-Dose	Intravenous	mg	190	4800	8000	17865	21006	29925
DMP 840	Intravenous	mg	1	173	173	173	173	173
Dacarbazine (DTIC)	Intravenous	mg	99	1349	1516	1968	2453	6250
Dactinomycin	Intravenous	mg	441	3	5	8	12	16
Dasatinib (Sprycel)	Oral	mg	1	.	.	.	.	.
Daunorubicin (Daunomycin)	Intravenous	mg	775	50	51	100	106	185
Dexamethasone (Decadron)	Intrathecal	mg	2	2	2	12	22	22
	Intravenous	mg	36	24	110	300	481	588
	Oral	mg	256	.	.	.	.	.
Docetaxel (Taxotere)	Intravenous	mg	14	200	231	400	441	631
Doxorubicin (Adriamycin)	Intravenous	mg	1104	119	154	198	316	384
Epirubicin	Intravenous	mg	4	83	177	335	426	452
Erwinia Asparaginase	Intramuscular	units	122	20000	49130	62333	128438	519231
	Intravenous	units	19	10171	19821	31356	49512	50870
Etopophos	Intravenous	mg	2	800	800	1200	1600	1600
Etoposide	Intravenous	mg	881	800	1226	4003	9883	14423
	Oral	mg	27	525	700	1100	1360	2123
Exemestane (Aromasin)	Oral	mg	1	.	.	.	.	.
Fludarabine	Intravenous	mg	12	60	60	60	120	200
Fluorouracil (5FU)	Intravenous	mg	44	2417	4146	12392	15652	17587
Gefitinib (Iressa, ZD1839)	Oral	mg	1	14000	14000	14000	14000	14000
Gemcitabine	Intravenous	mg	7	1000	1982	3960	8182	34037
Hydrocortisone	Intraommaya	mg	4	95	97	184	466	663
	Intrathecal	mg	755	104	214	332	480	632
	Intravenous	mg	2	379	379	2000	3621	3621
Hydroxyurea	Oral	mg	21	12298	17642	62990	100338	159574
Idarubicin	Intravenous	mg	27	10	11	20	36	58
Ifosfamide	Intravenous	mg	228	15077	24421	40691	57079	71405
Imatinib (Gleevec)	Oral	mg	2	80687	80687	80687	80687	80687
Interferon	Subcutaneous	million	3	70	70	505	992	992
Interferon Alpha-2a	Intramuscular	million	1	420	420	420	420	420
	Intravenous	million	1	1352	1352	1352	1352	1352
	Subcutaneous	million	8	14	159	224	546	887
Interferon Alpha-2b	Intramuscular	million	1	419	419	419	419	419

\*Study status as of June 30, 2015

Cumulative Dose (when known): Percentiles								
Chemotherapy Agent	Route	Units/m <sup>2</sup>	N	10th	25th	50th	75th	90th
	Intravenous	million	3	263	263	382	399	399
	Subcutaneous	million	7	121	735	1241	1428	1735
Interleukin-3	Subcutaneous	units	1	6248	6248	6248	6248	6248
Irinotecan (Camptosar)	Intravenous	mg	8	770	881	1148	1667	2547
Isotretinoin (Accutane)	Oral	mg	1	446	446	446	446	446
L-Asparaginase	Intramuscular	units	736	43448	59571	89639	126786	246939
	Intravenous	units	313	19688	20000	39506	40455	76981
Lomustine	Oral	mg	13	222	348	446	564	754
Mechlorethamine (Nitrogen Mustard)	Intravenous	mg	38	12	18	24	49	72
	Topical	mg	1	.	.	.	.	.
Melphalan	Intravenous	mg	10	88	90	130	140	218
Mercaptopurine	Intravenous	mg	169	1000	1000	1000	3000	4905
	Oral	mg	1152	10392	15147	21183	41774	49493
Methotrexate	Intramuscular	mg	304	440	911	1223	2518	3742
	Intraommaya	mg	8	8	32	79	91	150
	Intrathecal	mg	1235	56	77	151	222	316
	Intravenous	mg	803	121	362	1601	2686	3719
	Oral	mg	433	179	408	1766	2722	3949
Methotrexate: High-Dose	Intravenous	mg	841	4000	4075	15771	21844	45448
Methylprednisolone	Intravenous	mg	17	40	74	127	482	3753
	Oral	mg	1	4174	4174	4174	4174	4174
Mitomycin (Mutamycin)	Intravenous	mg	1	30	30	30	30	30
Mitotane	Oral	mg	1	709804	709804	709804	709804	709804
Mitoxantrone	Intravenous	mg	30	35	36	50	51	72
Nelarabine	Intravenous	mg	1	2000	2000	2000	2000	2000
Neuraminidase	Intravenous	units	1	6410	6410	6410	6410	6410
Oxaliplatin	Intravenous	mg	3	350	350	740	1000	1000
Paclitaxel	Intravenous	mg	9	120	690	853	976	1692
Peg-Asparaginase	Intramuscular	units	26	2500	4940	9999	15396	38250
Pemetrexed	Intravenous	mg	1	.	.	.	.	.
Prednisolone	Intravenous	mg	4	55	55	80	238	238
	Oral	mg	5	.	.	.	.	.
Prednisone	Oral	mg	1422	.	.	.	.	.

\*Study status as of June 30, 2015



Cumulative Dose (when known): Percentiles								
Chemotherapy Agent	Route	Units/m <sup>2</sup>	N	10th	25th	50th	75th	90th
Procarbazine	Oral	mg	224	2543	3557	4030	5660	7947
Rituximab	Intravenous	mg	6	375	751	1142	2237	2250
Tamoxifen	Oral	mg	10	204	959	4907	9903	10440
Temozolomide	Oral	mg	4	3821	3821	6300	17961	17961
Teniposide	Intravenous	mg	525	600	1361	3268	5314	6517
Thioguanine	Intravenous	mg	6	63	681	835	1731	1739
	Oral	mg	26	500	919	2816	11224	15674
Thiotepa	Intravenous	mg	20	79	283	422	900	903
Topotecan	Intrathecal		1	.	.	.	.	.
	Intravenous	mg	30	11	12	27	45	62
	Oral	mg	1	48	48	48	48	48
Trastuzumab	Intravenous	mg	2	2653	2653	3160	3667	3667
Tretinoin (Retin A)	Oral	mg	13	583	1639	1902	8144	16208
Trimetrexate	Intravenous	mg	1	1348	1348	1348	1348	1348
Vinblastine	Intravenous	mg	287	25	36	47	51	80
Vincristine	Intravenous	mg	2119	6	8	25	52	61
Vinorelbine	Intravenous	mg	3	25	25	49	150	150
Vismodegib (Erivedge)	Oral		1	.	.	.	.	.
XomaZyme	Intravenous	mg	3	41	41	67	69	69

**Table 6. Radiation Exposure among SJLIFE Campus Visit Participants by Primary Diagnosis and Treatment Field (N=3063)\***

Primary Diagnosis	Radiation Treatment Field - Potential Impact**						
	Total N	None N (%)	Any N (%)	Brain/Cranium N (%)	Chest N (%)	Abdomen N (%)	Pelvis N (%)
Acute lymphoblastic leukemia	1008	419 (41.6)	589 (58.4)	579 (57.4)	126 (12.5)	120 (11.9)	118 (11.7)
Acute myeloid leukemia	114	63 (55.3)	51 (44.7)	51 (44.7)	40 (35.1)	40 (35.1)	40 (35.1)
Other leukemia	21	3 (14.3)	18 (85.7)	17 (81.0)	18 (85.7)	18 (85.7)	17 (81.0)
Other hematologic malignancy	19	15 (78.9)	4 (21.1)	4 (21.1)	0 (0.0)	0 (0.0)	0 (0.0)
CNS tumor	312	99 (31.7)	213 (68.3)	210 (67.3)	101 (32.4)	102 (32.7)	102 (32.7)
Ewing sarcoma family of tumors	92	17 (18.5)	75 (81.5)	7 (7.6)	24 (26.1)	10 (10.9)	27 (29.3)
Osteosarcoma	116	110 (94.8)	6 (5.2)	2 (1.7)	2 (1.7)	0 (0.0)	0 (0.0)
Germ cell tumor	69	54 (78.3)	15 (21.7)	1 (1.4)	9 (13.0)	8 (11.6)	12 (17.4)
Hepatoblastoma	20	18 (90.0)	2 (10.0)	0 (0.0)	2 (10.0)	2 (10.0)	0 (0.0)
Hodgkin lymphoma	368	8 (2.2)	360 (97.8)	24 (6.5)	339 (92.1)	209 (56.8)	116 (31.5)
Non-Hodgkin lymphoma	223	129 (57.8)	94 (42.2)	49 (22.0)	45 (20.2)	28 (12.6)	30 (13.5)
Melanoma	16	14 (87.5)	2 (12.5)	1 (6.3)	1 (6.3)	0 (0.0)	0 (0.0)
Neuroblastoma	138	107 (77.5)	31 (22.5)	1 (0.7)	27 (19.6)	16 (11.6)	12 (8.7)
Retinoblastoma	90	49 (54.4)	41 (45.6)	41 (45.6)	0 (0.0)	0 (0.0)	1 (1.1)
RMS	107	19 (17.8)	88 (82.2)	45 (42.1)	18 (16.8)	13 (12.1)	38 (35.5)
Non-RMS	83	37 (44.6)	46 (55.4)	7 (8.4)	14 (16.9)	5 (6.0)	7 (8.4)
Wilms tumor	202	77 (38.1)	125 (61.9)	1 (0.5)	125 (61.9)	121 (59.9)	105 (52.0)
Carcinomas	47	18 (38.3)	29 (61.7)	28 (59.6)	2 (4.3)	0 (0.0)	2 (4.3)
Other malignancy	14	5 (35.7)	9 (64.3)	4 (28.6)	4 (28.6)	2 (14.3)	3 (21.4)
Other neoplasm	4	1 (25.0)	3 (75.0)	1 (25.0)	2 (50.0)	2 (50.0)	2 (50.0)
<b>All Diagnoses</b>	<b>3063</b>	<b>1262</b>	<b>1801</b>	<b>1073</b>	<b>899</b>	<b>696</b>	<b>632</b>

\*Study status as of June 30, 2015 \*\*Fields are not mutually exclusive

# SJLIFE Concept Registry

\\Stjude\data\SJShare\SJCOMMON\ECC\CPC Investigators

